The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myelomaAndrew Spencer, Christine Chen, Sung‐Soo Yoon et al.|Blood|2014Cited by 140
The natural history of CIN I lesions.Máire A. Duggan, Louis H. Honoré, Gavin Stuart et al.|PubMed|1998Cited by 51
Dose-Finding Quantitative <sup>18</sup>F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic MalignanciesHatice Güngör, Hani Gabra, Azeem Saleem et al.|Journal of Nuclear Medicine|2015Cited by 27
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.Hatice Güngör, Hani Gabra, Azeem Saleem et al.|Journal of Clinical Oncology|2011Cited by 14
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian CancerH. Gunqor, Hani Gabra, Edward Curry et al.|European Journal of Cancer|2011Cited by 1